Abnormal coagulation results in patients with Hodgkin's disease.
Case records of 177 patients admitted with Hodgkin's disease were reviewed to assess the frequency and significance of coagulation abnormalities. Prolongation of the prothrombin time, activated partial thromboplastin time, or thrombin time occurred in 56 patients, 32 percent of all evaluable cases. The most frequent clotting abnormalities involved the prothrombin time, which was increased in 43 patients (24 percent). Prothrombin time prolongation correlated with bulky or advanced disease as defined by stage (p = 0.001), constitutional symptoms (p less than 0.0001), massive mediastinal involvement (p = 0.02), and elevated alkaline phosphatase levels (p less than 0.0001). Abnormal coagulation test results followed the course of disease, normalizing with tumor regression and reappearing during relapse. Despite the surprising incidence of abnormal coagulation results, bleeding complications were reported in only two cases. Patients undergoing invasive procedures in the presence of clotting abnormalities fared no worse than those in whom procedures were cancelled. There is no evidence that complete staging evaluation should be comprised because of these abnormal test values. Extensive hematologic testing revealed no single mechanism to explain the coagulation factor disorders found in Hodgkin's disease.
Seifter
E J
EJ
Parker
R I
RI
Gralnick
H R
HR
Wesley
M
M
DeVita
V T
VT
Young
R C
RC
Longo
D L
DL
D000328:Adult; D001706:Biopsy; D001778:Blood Coagulation Disorders / Q000209:etiology*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006689:Hodgkin Disease / Q000150:complications*; D006801:Humans; D010535:Laparoscopy; D008099:Liver / Q000473:pathology; D008297:Male; D010314:Partial Thromboplastin Time; D010976:Platelet Count; D011517:Prothrombin Time; D013918:Thrombin Time; D013922:Thrombocytosis / Q000209:etiology; D014813:Vitamin K Deficiency / Q000209:etiology
D005340:Fibrinogen